Our results demonstratedthat DIA offers unbiased and 2–3-fold more comprehensive glycopeptidecoverage, especially significantly fucosylated and combined fucosylated-sialylatedglycans in individual patients, and 54 unique Hp glycopeptides exclusivelypresent in HCC patients. Here, HP is linked to hepatocellular carcinoma.